-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The National Medical Insurance Administration issued a reply letter to the committee’s proposal on September 24.
Regarding the effectiveness of centralized procurement, “Centralized mass procurement can push prices back to a reasonable level by squeezing out the false high price of medicines, reducing the burden on patients, and promoting cleanliness.
The formation of a business environment and a medical practice environment has led the pharmaceutical industry to shift from high-speed growth to high-quality development
.
” At the same time, a set of data in the reply shows that in 2020, the sales expenses of listed A-share pharmaceutical companies have shown a downward trend for the first time in the past five years.
A year-on-year decrease of 6%, R&D expenses increased by 22% year-on-year
.
This shows that pharmaceutical companies are shifting from focusing on sales to focusing on research and development
.
At the same time, the enthusiasm of generic drug companies to promote consistency evaluation has not only improved the level of drug use by patients in China, but also supported the innovation and development of the industry
.
It is understood that in recent years, with the implementation of policies such as "generic drug consistency evaluation", "quantity procurement", and "medical insurance negotiation", the pharmaceutical industry is facing tremendous adjustments
.
In this context, China's innovative drug companies are paying more and more attention to R&D investment in innovative drugs
.
Many pharmaceutical companies have continuously increased their investment in research and development
.
According to data, in 2020, Hengrui Pharmaceutical's R&D investment will increase by 28% year-on-year to 4.
989 billion yuan, accounting for 18% of operating income
.
In the first half of 2021, its R&D investment increased by 38.
48% year-on-year to 2.
581 billion yuan, and R&D investment accounted for 19.
41% of sales revenue
.
The company stated that it will further increase R&D investment as R&D needs in the future
.
BeiGene's R&D expenses in 2020 totaled RMB 8.
3 billion, a year-on-year increase of 39.
11%
.
In the first half of 2021, BeiGene's R&D expenditure reached 677 million US dollars (approximately 4.
38 billion yuan), a further increase of 14.
7% year-on-year, accounting for 89.
5% of revenue
.
In addition, in the first half of this year, Xinlitai’s R&D investment reached 331 million yuan, a year-on-year increase of 39.
56%; Renfu Pharmaceutical’s R&D expenditure was nearly 400 million yuan, a year-on-year increase of 8.
65%; Huadong Pharmaceutical’s investment reached 536 million yuan, a year-on-year increase of 6.
38%
.
"Emphasis on sales rather than R&D" has always been the "heart disease" of China's pharmaceutical industry.
However, in recent years, as the cost of pharmaceutical R&D has risen year by year, and the implementation of "quantity procurement" has entered the background, pharmaceutical companies have gradually moved towards Transition stage
.
Many pharmaceutical companies realize that only by focusing on R&D can they live better, and they have also begun to increase their investment in R&D and innovation
.
According to the data, among the 384 listed companies in the pharmaceutical industry classified by CITIC, 73 listed companies invested more than 100 million yuan in research and development in the first half of the year, compared with 53 in the same period last year.
Among them, the number of listed companies in the chemical pharmaceutical and biomedical sectors has researched and developed more than 100 million yuan.
The largest number are 29 and 16 respectively
.
In addition, some people pointed out that compared with last year, in addition to increasing R&D investment for pharmaceutical companies this year, R&D projects are diversified, including generic drugs, biosimilar drugs, bio-innovative drugs, and small-molecule innovative drugs.
Many pharmaceutical companies have formed from easy to difficult.
Has established its own R&D echelon
.
Pharmaceutical distribution companies have also changed their previous remarketing image and carried out research and development of innovative drug pipelines
.
It is understood that the current rapid development of China's innovative drug industry, the enthusiasm for new drug research and development is high
.
According to the application progress database of Insight database, a data platform for the pharmaceutical industry, a total of 179 new drugs were approved for clinical use in July, involving 110 varieties
.
Among domestic companies, seven new drugs from Hengrui Pharmaceuticals were approved for clinical use, four new drugs from BeiGene were approved for clinical use, and three new drugs from Cinda Biotech were also approved for clinical use
.
Driven by policies, R&D investment in the pharmaceutical industry will continue to increase in the future
.
For example, Yuandong Biology stated that the company continues to maintain high R&D investment and has a rich layout in research pipelines
.
Enhua Pharmaceuticals also stated that the company will continue to steadily promote the research and development of innovative drugs and high-barrier generic drugs, and mentioned that the company must invest a large amount of funds for drug R&D and innovation every year based on the needs of future development.
Sexual evaluation
.
Regarding the effectiveness of centralized procurement, “Centralized mass procurement can push prices back to a reasonable level by squeezing out the false high price of medicines, reducing the burden on patients, and promoting cleanliness.
The formation of a business environment and a medical practice environment has led the pharmaceutical industry to shift from high-speed growth to high-quality development
.
” At the same time, a set of data in the reply shows that in 2020, the sales expenses of listed A-share pharmaceutical companies have shown a downward trend for the first time in the past five years.
A year-on-year decrease of 6%, R&D expenses increased by 22% year-on-year
.
This shows that pharmaceutical companies are shifting from focusing on sales to focusing on research and development
.
At the same time, the enthusiasm of generic drug companies to promote consistency evaluation has not only improved the level of drug use by patients in China, but also supported the innovation and development of the industry
.
It is understood that in recent years, with the implementation of policies such as "generic drug consistency evaluation", "quantity procurement", and "medical insurance negotiation", the pharmaceutical industry is facing tremendous adjustments
.
In this context, China's innovative drug companies are paying more and more attention to R&D investment in innovative drugs
.
Many pharmaceutical companies have continuously increased their investment in research and development
.
According to data, in 2020, Hengrui Pharmaceutical's R&D investment will increase by 28% year-on-year to 4.
989 billion yuan, accounting for 18% of operating income
.
In the first half of 2021, its R&D investment increased by 38.
48% year-on-year to 2.
581 billion yuan, and R&D investment accounted for 19.
41% of sales revenue
.
The company stated that it will further increase R&D investment as R&D needs in the future
.
BeiGene's R&D expenses in 2020 totaled RMB 8.
3 billion, a year-on-year increase of 39.
11%
.
In the first half of 2021, BeiGene's R&D expenditure reached 677 million US dollars (approximately 4.
38 billion yuan), a further increase of 14.
7% year-on-year, accounting for 89.
5% of revenue
.
In addition, in the first half of this year, Xinlitai’s R&D investment reached 331 million yuan, a year-on-year increase of 39.
56%; Renfu Pharmaceutical’s R&D expenditure was nearly 400 million yuan, a year-on-year increase of 8.
65%; Huadong Pharmaceutical’s investment reached 536 million yuan, a year-on-year increase of 6.
38%
.
"Emphasis on sales rather than R&D" has always been the "heart disease" of China's pharmaceutical industry.
However, in recent years, as the cost of pharmaceutical R&D has risen year by year, and the implementation of "quantity procurement" has entered the background, pharmaceutical companies have gradually moved towards Transition stage
.
Many pharmaceutical companies realize that only by focusing on R&D can they live better, and they have also begun to increase their investment in R&D and innovation
.
According to the data, among the 384 listed companies in the pharmaceutical industry classified by CITIC, 73 listed companies invested more than 100 million yuan in research and development in the first half of the year, compared with 53 in the same period last year.
Among them, the number of listed companies in the chemical pharmaceutical and biomedical sectors has researched and developed more than 100 million yuan.
The largest number are 29 and 16 respectively
.
In addition, some people pointed out that compared with last year, in addition to increasing R&D investment for pharmaceutical companies this year, R&D projects are diversified, including generic drugs, biosimilar drugs, bio-innovative drugs, and small-molecule innovative drugs.
Many pharmaceutical companies have formed from easy to difficult.
Has established its own R&D echelon
.
Pharmaceutical distribution companies have also changed their previous remarketing image and carried out research and development of innovative drug pipelines
.
It is understood that the current rapid development of China's innovative drug industry, the enthusiasm for new drug research and development is high
.
According to the application progress database of Insight database, a data platform for the pharmaceutical industry, a total of 179 new drugs were approved for clinical use in July, involving 110 varieties
.
Among domestic companies, seven new drugs from Hengrui Pharmaceuticals were approved for clinical use, four new drugs from BeiGene were approved for clinical use, and three new drugs from Cinda Biotech were also approved for clinical use
.
Driven by policies, R&D investment in the pharmaceutical industry will continue to increase in the future
.
For example, Yuandong Biology stated that the company continues to maintain high R&D investment and has a rich layout in research pipelines
.
Enhua Pharmaceuticals also stated that the company will continue to steadily promote the research and development of innovative drugs and high-barrier generic drugs, and mentioned that the company must invest a large amount of funds for drug R&D and innovation every year based on the needs of future development.
Sexual evaluation
.
